FLAURA trial: overall survival results confirms the efficacy of osimertinib in the treatment of NSCLC

Prof. Martin-Reck

Final overall survival (OS) data from FLAURA trial presented at ESMO Congress 2019 confirm that osimertinib is an option for first-line treatment of patients with EGFR-mutated NSCLC, as reported by Prof. Martin Reck from Prof. Martin Reck, Krankenhaus Grosshansdorf, Grosshansdorf, Germany.ESMO Congress 2019 abstract:LBA5_PR - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Related content

Legal
Change cookie settings
Useful links
Get our news straight to your box

Subscribe to the ESMO Daily Reporter Alert and find out the latest advances in cancer care with our news and interviews to international experts. To receive the alert on a regular basis, create or login to your ESMO account and opt-in.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2024 European Society for Medical Oncology All rights reserved worldwide.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.